← Leaderboards
Natella Y Rakhmanina
Children'S Research Institute
$1,136,766
Attributed
$1,136,766
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $617.3K · FY2006–10$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$1,136,766 · 8
By mechanism
M01$1,136,766 · 8
Top collaborators
No co-investigators on record.
Most similar at Children'S Research Institute
Same institution · by research overlap
- Daniel J Merenstein$17,048,763
- Natella Yurievna Rakhmanina$1,964,549
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Judith S. Currier · University Of California Los Angeles$284,675,012
Research focus
Research PersonnelGrantFundingComputer Retrieval Of Information On Scientific Projects DatabaseUnited States National Institutes Of HealthDoseInstitutionDrug KineticsSourceResourcesChildhoodViral Load ResultChildCd4 Lymphocyte CountOutcome MeasureGeneticBaseCohortAdolescentPharmaceutical PreparationsToxic EffectClassificationAntiretroviral TherapyCytochrome P-450 Cyp3a5 (Human)
Grant awards (8)
PHARMACOKINETICS OF LOPINAVIR CRUSHED VERSUS WHOLE TABLETS: HIV$14,591
M01 · FY2010 · RR · contact PI
EFFECT OF PUBERTY ON THE PHARMACOKINETICS OF EFAVIRENZ IN HIV-INFECTED CHILDREN$6,253
M01 · FY2010 · RR · contact PI
OPTIMIZING ANTIRETROVIRAL THERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS$2,085
M01 · FY2010 · RR · contact PI
OPTIMIZING ANTIRETROVIRAL THERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS$158,648
M01 · FY2009 · RR · contact PI
PHARMACOKINETICS OF LOPINAVIR CRUSHED VERSUS WHOLE TABLETS$9,625
M01 · FY2009 · RR · contact PI
OPTIMIZING ANTIRETROVIRAL THERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS$617,342
M01 · FY2008 · RR · contact PI
OPTIMIZING ANTIRETROVIRAL THERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS$155,212
M01 · FY2007 · RR · contact PI
OPTIMIZING ANTIRETROVIRAL THERAPY IN HIV-INFECTED CHILDREN AND ADOLESCENTS$173,010
M01 · FY2006 · RR · contact PI